pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-6787 |
Genomic Coordinates | chr17: 82236668 - 82236728 |
Description | Homo sapiens miR-6787 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-6787-5p | ||||||||||||||||||||||||||||||||||||
Sequence | 6| UGGCGGGGGUAGAGCUGGCUGC |27 | ||||||||||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||||||||||
Experiments | Meta-analysis | ||||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||||||||||
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | VAV3 | ||||||||||||||||||||
Synonyms | - | ||||||||||||||||||||
Description | vav guanine nucleotide exchange factor 3 | ||||||||||||||||||||
Transcript | NM_001079874 | ||||||||||||||||||||
Other Transcripts | NM_006113 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on VAV3 | |||||||||||||||||||||
3'UTR of VAV3 (miRNA target sites are highlighted) |
>VAV3|NM_001079874|3'UTR 1 ATTCAAATCCCGTGTTGCACCCTGCACCAAAAATTTCAGAGAAGGGATAAATAGAAGCCTGCACAGCATCGTGAATTAAC 81 TGAAGTGTTTAAAAAGCTGCATTTCTGGCTGTTCAACATCCTCCCTCCTTAGCCCCTCCTAAGTCTTAATGCTGAGATTT 161 CTAAAGATGCTGGTACTGACAGATTAATGGCTTGCCTAGAGCTGTGCAAGAAACAGCCTGCCAGTCTGTCATTGTCAGGG 241 ACCAGGGCAAAACCAAGAGCTGTTCTTCCCAGAAGAGCCCTGCAAACACATTGGTTCGTGCTTCCCTTTACTTCTTCTGG 321 TCAGATACCATGAATGCCAGTCATCAGTAAATCTTAATACACTTTTGCTTTATTCTCACATGCCATTCACCAGATTATTT 401 GATGGTACAAAGAAGCAGAAGTGTAATTTTCCTTTTCCCAGCATGACGAAAAATTGGAGTTCTGCCATTTGAGCAGCTTA 481 CTGGAAAGATCCAGCCTTACTTGTCTTAAATTGTCCAACAAGGTGACTCATTGCCCGGCAAACACTTTTACCCTCAGATG 561 TTACTCATGATATTATAAAATATGAGGCCAGTGCTCAGGTTTGCATCATAAGTGAGCTATCCCTGAAGGGTTTTAATTAC 641 TTATTTGGTGTCCTGATTATATTTGCAAACTTCTTTATAAAAGGTGAAAAAAGCACACAAAAGAGAGGGTGTCTTCATAT 721 TAAACCTTCACAACCTTCATGATTTCATAGGATTATTTTGGAAATATAGCACTTGACTTTATGAAAGGATCTGGGCTAGG 801 TATATTAAGGGTAGTTGCCAATAACCTGAAGAAGCTGGCATTGTTTACAGAAACAGATCAAGGGCTATAATTTATGTCAT 881 TTTATAGCAGCAGTATCTATTAATACATGCCTTTTCCTCCCATCCACCTCCCCCGCACACACACAAAGATGACCTGGGAC 961 ATGATTTTTTTATTCCCACATTTTCTTGGAGCACAAACAACTTTGTTGAGGATTTTGGAAGGAAAGCACAACTGGGTCCT 1041 TTATTCATTTCTGGGACAGAAAGAGGGTCAGTGGACTTTTGTGGGCCTCCAGCTTCTCTCAGAGTCTCCCCCTCTGCAGC 1121 CCATCCTGGGAGTGTATTAACTGGAGGGAAGATGGGTCTTGCAGTACATTTGTTTTGCCCAGCCATCACTCTTTTTTGTG 1201 AGGAGCCTAAATACATTCTTCCTGGGGTCCAGAGTCCCCATTCAAGGCAGTCAAGTTAAGACACTAACTTGGCCCTTTCC 1281 TGATGGAAATATTTCCTCCATAGCAGAAGTTGTGTTCTGACAAGACTGAGAGAGTTACATGTTGGGAAAAAAAAGAAGCA 1361 TTAACTTAGTAGAACTGAACCAGGAGCATTAAGTTCTGAAATTTTGAATCATCTCTGAAATGAAGCAGGTGTAGCCTGCC 1441 CTCTCATCAATCCGTCTGGGTGCCAGAACTCAAGGTTCAGTGGACACATCCCCCTGTTAGAGACCCTCATGGGCTAGGAC 1521 TTTTCATCTAGGATAGATTCAAGACCTTTACCTCAGAATTATGTAAACTGTGATTGTGTTTTAGAAAAATTATTATTTGC 1601 TAAAACCATTTAAGTCTTTGTATATGTGTAAATGATCACAAAAATGTATTTTATAAAATGTTCTGTACAATAAAGTTACA 1681 CCTCAAAGTGTACTCTTGGAATGGATTCTTTCCTGTAAAGTCTTATCTGCGACTCTGTCTCGGGAATGTTTTGTCTGTTG 1761 CCGTCAGCCGAACTTTGTTATGGAGGGAGCAGCCTCACACAAGCAGAAACACTCCTGTGGATGGTATTGTAGCATGTATT 1841 GTTTATTTTAGTCAATAGACCCTCTCCTTATAAATGGTGTTTAGTCTTCCTGTTGCATTTCATGGGCCTGGGGGTTTCCT 1921 AGCAGAGGATATTGGAGCCCCTTTTTGTGACATTACCAATTACATCTTTGTCCACGTTTAATACTTTGTTTTGGAAAATT 2001 TAAATGCTGCAGATTTGTGTAGAGTTCTAATACCAAAGACAGAAGTAAATGTTTTCCATATACTTTGTCTTGCCTGTATG 2081 CAGCCCTCGTGTAATACGGTGAATTAGAGTGGTATTTCACTTTGTATTATTTTGTAAATATGTCAATATAATAAATAGTG 2161 ACTAAATTGATAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545215. RNA binding protein: AGO4. Condition:Control
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | hESCs (WA-09) | ||||||
Disease | 10451.0 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in SRR359787. RNA binding protein: AGO2. Condition:4-thiouridine
... - Lipchina I; Elkabetz Y; Hafner M; Sheridan et al., 2011, Genes & development. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Lipchina I; Elkabetz Y; Hafner M; Sheridan et al. - Genes & development, 2011
MicroRNAs are important regulators in many cellular processes, including stem cell self-renewal. Recent studies demonstrated their function as pluripotency factors with the capacity for somatic cell reprogramming. However, their role in human embryonic stem (ES) cells (hESCs) remains poorly understood, partially due to the lack of genome-wide strategies to identify their targets. Here, we performed comprehensive microRNA profiling in hESCs and in purified neural and mesenchymal derivatives. Using a combination of AGO cross-linking and microRNA perturbation experiments, together with computational prediction, we identified the targets of the miR-302/367 cluster, the most abundant microRNAs in hESCs. Functional studies identified novel roles of miR-302/367 in maintaining pluripotency and regulating hESC differentiation. We show that in addition to its role in TGF-beta signaling, miR-302/367 promotes bone morphogenetic protein (BMP) signaling by targeting BMP inhibitors TOB2, DAZAP2, and SLAIN1. This study broadens our understanding of microRNA function in hESCs and is a valuable resource for future studies in this area.
LinkOut: [PMID: 22012620]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | TZM-bl |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
Experimental Support 4 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | Prostate Tissue |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRX1760628. RNA binding protein: AGO2. Condition:AGO-CLIP-LAPC4_B
PAR-CLIP data was present in SRX1760616. RNA binding protein: AGO2. Condition:AGO-CLIP-PC3_A
PAR-CLIP data was present in SRX1760618. RNA binding protein: AGO2. Condition:AGO-CLIP-PC3_B
PAR-CLIP data was present in SRX1760631. RNA binding protein: AGO2. Condition:AGO-CLIP-22RV1_B
... - Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al., 2016, Neoplasia (New York, N.Y.). |
Article |
- Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al. - Neoplasia (New York, N.Y.), 2016
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally, tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the miRNA target spectrum responds to staged tumorigenesis.
LinkOut: [PMID: 27292025]
|
CLIP-seq Support 1 for dataset GSM545215 | |
---|---|
Method / RBP | PAR-CLIP / AGO4 |
Cell line / Condition | HEK293 / Control |
Location of target site | ENST00000370056.4 | 3UTR | CAGCCCCGUGGACGCUA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset SRR359787 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | hESCs (WA-09) / 4-thiouridine, RNase T1 |
Location of target site | ENST00000370056.4 | 3UTR | AGCCCCGUGGACGCUA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22012620 / SRX103431 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM1462574 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl ami BaL |
Location of target site | ENST00000370056.4 | 3UTR | AGCCCCGUGGACGCU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
90 hsa-miR-6787-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT449091 | XPO6 | exportin 6 | 2 | 2 | ||||||||
MIRT449991 | PSMG1 | proteasome assembly chaperone 1 | 2 | 2 | ||||||||
MIRT454608 | MYADM | myeloid associated differentiation marker | 2 | 2 | ||||||||
MIRT456116 | VAV3 | vav guanine nucleotide exchange factor 3 | 2 | 6 | ||||||||
MIRT457064 | TOR4A | torsin family 4 member A | 2 | 2 | ||||||||
MIRT461023 | SDF4 | stromal cell derived factor 4 | 2 | 2 | ||||||||
MIRT467197 | SPRY4 | sprouty RTK signaling antagonist 4 | 2 | 2 | ||||||||
MIRT471711 | OTUB1 | OTU deubiquitinase, ubiquitin aldehyde binding 1 | 2 | 2 | ||||||||
MIRT472566 | NACC1 | nucleus accumbens associated 1 | 2 | 2 | ||||||||
MIRT476079 | GRB2 | growth factor receptor bound protein 2 | 2 | 2 | ||||||||
MIRT480150 | CALR | calreticulin | 2 | 2 | ||||||||
MIRT483027 | KHSRP | KH-type splicing regulatory protein | 2 | 4 | ||||||||
MIRT483498 | STMN3 | stathmin 3 | 2 | 4 | ||||||||
MIRT483728 | THSD4 | thrombospondin type 1 domain containing 4 | 2 | 2 | ||||||||
MIRT484550 | BARHL1 | BarH like homeobox 1 | 2 | 6 | ||||||||
MIRT484684 | PACSIN1 | protein kinase C and casein kinase substrate in neurons 1 | 2 | 2 | ||||||||
MIRT486059 | CTDNEP1 | CTD nuclear envelope phosphatase 1 | 2 | 2 | ||||||||
MIRT486116 | INO80E | INO80 complex subunit E | 2 | 2 | ||||||||
MIRT486313 | SIPA1 | signal-induced proliferation-associated 1 | 2 | 2 | ||||||||
MIRT486525 | CLCN7 | chloride voltage-gated channel 7 | 2 | 2 | ||||||||
MIRT486857 | DPF1 | double PHD fingers 1 | 2 | 2 | ||||||||
MIRT487352 | PHF15 | jade family PHD finger 2 | 1 | 1 | ||||||||
MIRT487582 | FAM83H | family with sequence similarity 83 member H | 2 | 4 | ||||||||
MIRT487792 | GPR20 | G protein-coupled receptor 20 | 2 | 4 | ||||||||
MIRT488104 | POU3F1 | POU class 3 homeobox 1 | 2 | 2 | ||||||||
MIRT488786 | POFUT2 | protein O-fucosyltransferase 2 | 2 | 2 | ||||||||
MIRT489361 | SYNGR1 | synaptogyrin 1 | 2 | 4 | ||||||||
MIRT489387 | RAB11B | RAB11B, member RAS oncogene family | 2 | 2 | ||||||||
MIRT489680 | SCAMP4 | secretory carrier membrane protein 4 | 2 | 2 | ||||||||
MIRT489731 | GNAI2 | G protein subunit alpha i2 | 2 | 4 | ||||||||
MIRT489750 | TACC3 | transforming acidic coiled-coil containing protein 3 | 2 | 2 | ||||||||
MIRT490029 | PCSK4 | proprotein convertase subtilisin/kexin type 4 | 2 | 2 | ||||||||
MIRT490379 | LHFPL3 | LHFPL tetraspan subfamily member 3 | 2 | 2 | ||||||||
MIRT490580 | SLC47A1 | solute carrier family 47 member 1 | 2 | 2 | ||||||||
MIRT490753 | SRCIN1 | SRC kinase signaling inhibitor 1 | 2 | 2 | ||||||||
MIRT491187 | JUND | JunD proto-oncogene, AP-1 transcription factor subunit | 2 | 4 | ||||||||
MIRT491301 | VGF | VGF nerve growth factor inducible | 2 | 2 | ||||||||
MIRT491462 | HOXB8 | homeobox B8 | 2 | 2 | ||||||||
MIRT491702 | PDZD4 | PDZ domain containing 4 | 2 | 2 | ||||||||
MIRT491724 | RTN4R | reticulon 4 receptor | 2 | 2 | ||||||||
MIRT491737 | SEMA3F | semaphorin 3F | 2 | 2 | ||||||||
MIRT491984 | UNK | unkempt family zinc finger | 2 | 2 | ||||||||
MIRT492844 | NRGN | neurogranin | 2 | 2 | ||||||||
MIRT492936 | NEUROD2 | neuronal differentiation 2 | 2 | 4 | ||||||||
MIRT493713 | H2AFX | H2A histone family member X | 2 | 2 | ||||||||
MIRT494623 | ASB6 | ankyrin repeat and SOCS box containing 6 | 2 | 4 | ||||||||
MIRT494703 | ARHGAP31 | Rho GTPase activating protein 31 | 2 | 2 | ||||||||
MIRT495602 | NKX2-5 | NK2 homeobox 5 | 2 | 2 | ||||||||
MIRT495750 | PDE4C | phosphodiesterase 4C | 2 | 4 | ||||||||
MIRT500367 | ZNF385A | zinc finger protein 385A | 2 | 2 | ||||||||
MIRT501161 | SLC10A7 | solute carrier family 10 member 7 | 2 | 6 | ||||||||
MIRT501702 | PCGF3 | polycomb group ring finger 3 | 2 | 6 | ||||||||
MIRT504922 | PDRG1 | p53 and DNA damage regulated 1 | 2 | 2 | ||||||||
MIRT517945 | TRIM59 | tripartite motif containing 59 | 2 | 2 | ||||||||
MIRT524212 | DDI2 | DNA damage inducible 1 homolog 2 | 2 | 6 | ||||||||
MIRT531186 | SIGLEC12 | sialic acid binding Ig like lectin 12 (gene/pseudogene) | 2 | 2 | ||||||||
MIRT531972 | C12orf49 | chromosome 12 open reading frame 49 | 2 | 2 | ||||||||
MIRT558055 | EVI5L | ecotropic viral integration site 5 like | 2 | 2 | ||||||||
MIRT560482 | LACE1 | AFG1 like ATPase | 2 | 2 | ||||||||
MIRT563217 | FXN | frataxin | 2 | 2 | ||||||||
MIRT569095 | FSCN1 | fascin actin-bundling protein 1 | 2 | 2 | ||||||||
MIRT569522 | AP5Z1 | adaptor related protein complex 5 zeta 1 subunit | 2 | 2 | ||||||||
MIRT569531 | CTTN | cortactin | 2 | 2 | ||||||||
MIRT569848 | RGS5 | regulator of G protein signaling 5 | 2 | 2 | ||||||||
MIRT570738 | ANKRD52 | ankyrin repeat domain 52 | 2 | 2 | ||||||||
MIRT574140 | MARVELD1 | MARVEL domain containing 1 | 2 | 2 | ||||||||
MIRT615994 | DHTKD1 | dehydrogenase E1 and transketolase domain containing 1 | 2 | 2 | ||||||||
MIRT628493 | ZNF556 | zinc finger protein 556 | 2 | 2 | ||||||||
MIRT633451 | KLLN | killin, p53-regulated DNA replication inhibitor | 2 | 2 | ||||||||
MIRT649054 | SLC1A2 | solute carrier family 1 member 2 | 2 | 2 | ||||||||
MIRT649340 | HEXA | hexosaminidase subunit alpha | 2 | 2 | ||||||||
MIRT670226 | PTCHD1 | patched domain containing 1 | 2 | 2 | ||||||||
MIRT670666 | KIAA1551 | KIAA1551 | 2 | 2 | ||||||||
MIRT671452 | CDH7 | cadherin 7 | 2 | 2 | ||||||||
MIRT671729 | ZNF451 | zinc finger protein 451 | 2 | 2 | ||||||||
MIRT690285 | ZNF154 | zinc finger protein 154 | 2 | 2 | ||||||||
MIRT700575 | PRSS22 | protease, serine 22 | 2 | 2 | ||||||||
MIRT701411 | NKRF | NFKB repressing factor | 2 | 2 | ||||||||
MIRT711877 | VASP | vasodilator stimulated phosphoprotein | 2 | 2 | ||||||||
MIRT712082 | UNC13A | unc-13 homolog A | 2 | 2 | ||||||||
MIRT712523 | CYTH2 | cytohesin 2 | 2 | 2 | ||||||||
MIRT712751 | GMDS | GDP-mannose 4,6-dehydratase | 2 | 2 | ||||||||
MIRT714681 | PRX | periaxin | 2 | 2 | ||||||||
MIRT714718 | VPS8 | VPS8, CORVET complex subunit | 2 | 2 | ||||||||
MIRT717508 | HRNR | hornerin | 2 | 2 | ||||||||
MIRT717650 | THBS2 | thrombospondin 2 | 2 | 2 | ||||||||
MIRT719592 | PIAS4 | protein inhibitor of activated STAT 4 | 2 | 2 | ||||||||
MIRT720521 | PTGR2 | prostaglandin reductase 2 | 2 | 2 | ||||||||
MIRT721295 | C3orf36 | chromosome 3 open reading frame 36 | 2 | 2 | ||||||||
MIRT724922 | VPS18 | VPS18, CORVET/HOPS core subunit | 2 | 2 |
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|